Reported about 23 hours ago
H.C. Wainwright has maintained a Buy rating on Stoke Therapeutics (NASDAQ:STOK), setting a price target of $35, due to the promising potential of its drug Zorevunersen for treating Dravet syndrome. Analyst Ananda Ghosh highlighted the positive long-term effects observed in the drug's trials, suggesting it could become the first disease-modifying therapy for the condition. Although STOK shows promise as an investment, it is suggested that some AI stocks may offer better potential returns.
Source: YAHOO